NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the firm earned ($0.24) EPS. View Spectrum Pharmaceuticals' Earnings History.

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

5 equities research analysts have issued twelve-month price targets for Spectrum Pharmaceuticals' stock. Their forecasts range from $4.00 to $21.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $13.20 in the next twelve months. This suggests a possible upside of 366.4% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

News articles about SPPI stock have trended negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 13,050,000 shares, an increase of 13.9% from the January 15th total of 11,460,000 shares. Based on an average trading volume of 2,311,200 shares, the days-to-cover ratio is currently 5.6 days. Approximately 13.3% of the shares of the stock are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Zynerba Pharmaceuticals (ZYNE), TG Therapeutics (TGTX), AT&T (T), Amicus Therapeutics (FOLD), Novavax (NVAX) and Verastem (VSTM).

Spectrum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), FMR LLC (1.23%), Bank of New York Mellon Corp (1.12%), ArrowMark Colorado Holdings LLC (0.95%) and Candriam Luxembourg S.C.A. (0.88%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., UBS Group AG and Arizona State Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

SPPI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Bank of New York Mellon Corp, Teza Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $2.83.